Edap Tms S.a.·Healthcare

Edap Tms (NASDAQ: EDAP) reported what management called a "transformative" 2025, driven by strong growth in its core high-intensity focused ultrasound (HIFU) business and record commercial performance for its Focal One platform. On the company's fourth-quarter and year-end 2025 earnings call, executives highlighted accelerating adoption in the U.S., record system placements, and rising procedure volumes that

EDAP TMS S.A. (EDAP) Q4 2025 Earnings Call Transcript

EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S. Focal One Procedures 69% Full-Year YoY Growth in Focal One System Placements 28% Q4 YoY Growth in U.S. Procedures, Marking the Second Consecutive Quarter of Double-Digit Procedure Growth Demand for Focal One Systems Remains Strong with System Placements in Academic Cancer Centers, Community Hospitals, and Large Integrated Healthcare Networks Company Reiterates its Previously Issued 2026 Revenue Guidance; HIFU Revenue Expected to Grow Between 34% and 45% YoY AUSTIN, Texas, March 25, 2026 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today financial results for the fourth quarter and full-year 2025. “We experienced strong global demand for Focal One Robotic HIFU as demonstrated by our 2025 results,” said Ryan Rhodes, Chief Executive Officer.

Edap Tms (NASDAQ: EDAP - Get Free Report) is projected to post its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect Edap Tms to post earnings of ($0.16) per share and revenue of $21.28 million for the quarter. Interested persons may visit the the company's upcoming Q4 2025 earning results page

EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference Company to Present and Host 1x1 Investor Meetings on Wednesday, March 18 th , 2026 AUSTIN, Texas, March 10, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and, together with Ken Mobeck, Chief Financial Officer, will host 1x1 investor meetings at the upcoming Oppenheimer 36th Annual Healthcare MedTech & Services Conference. Date: Wednesday, March 18th Time: 12:00-12:30 PM ET Format: Virtual Presentation and 1x1 investor meetings Webcast:https://event.summitcast.com/view/2MZVg3DCx8a3zxe3mMMekq/6YGp8gAgsNuJhACXjn75JB The live and archived webcast of the presentation can be accessed in the Investors section of the Company's website here.

Paradigm Medical Industries (OTCMKTS:PDMI - Get Free Report) and Edap Tms (NASDAQ: EDAP - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends. Profitability This table compares Paradigm Medical Industries
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
Healthcare
Medical - Devices
310
1997-08-01
-0.08